| 靶点: |
IC50: 30 nM (soluble Guanylyl Cyclase sGC) |
| 体内研究: |
NS -2028 (口服给药;1 g/L;8 天) 在 VEGF 颗粒植入后,无血管兔角膜的新血管形成显著减少。 |
| 参考文献: |
1. Olesen SP, et al. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol. 1998 Jan;123(2):299-309. 2. Morbidelli L, et al. The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R824-32. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.717 ml |
18.584 ml |
37.168 ml |
| 5 mM |
0.743 ml |
3.717 ml |
7.434 ml |
| 10 mM |
0.372 ml |
1.858 ml |
3.717 ml |
| 50 mM |
0.074 ml |
0.372 ml |
0.743 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |